Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents--their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. The previous edition was one of "Doody's Core Titles 2009." This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised.

Section 1: BASIC PRINCIPLES OF CANCER TREATMENT 1: Clinical Strategies for Cancer Treatment: The Role of Drugs Bruce Chabner 2: Target Identification and Drug Discovery Ed Sausville 3: Clinical Drug Development and Approval for Marketing Thomas Roberts 4: Principles of Pharmacokinetics Jerry Collins 5: Special Aspects of Brain Tumor Chemotherapy Jeffrey Supko & Tracy Batchelor 6: Pharmacogenetics Howard McLeod 7: Barriers to Drug Delivery Brendan Curti Section 2: CYTOTOXIC AGENTS 8: Antifolates Carmen Allegra & Bruce Chabner 9: Fluoro-pyrimidines David Ryan, Bruce Chabner & Ray Wadlow 10: Cytidine Analogues David Ryan & Bruce Chabner 11: Purine Analogues Ken Hande 12: Hydroxyurea Bruce Chabner 13: Antimitotic Drugs Ross Donehower 14: Alkylating Agents (Including Methylating Agents) Stan Gerson & Henry Friedman 15: Platinum Analogues Ed Reed 16: Antitumor Antibiotics (Including Bleomycin) Bruce Chabner 17: Topoisomerase I Inhibitors Alex Spaareboom & William Zamboni 18: Topoisomerase II Inhibitors: Anthracyclines Jim Doroshow 19: Topoisomerase II Inhibitors: Etoposide, Teniposide George Hartman & Yves Pommier 20: L-Asparaginase Bruce Chabner & Alison Friedmann Section 3: MOLECULARLY TARGETED THERAPIES 21: Proteosome Inhibitors Orhan Sezar 22: HDAC Inhibitors Susan Bates 23: Differentiating Agents (Retinoids) Bruce Chabner 24: Arsenic Trioxide Bruce Chabner 25: Monoclonal Antibodies: Discovery & Development David Scheinberg 26: Anti-angiogenic Agents (Including MonAB) William Gradishar & Kari Wisinski 27: Anti-EGFR Therapies (Including MonAB) Lecia Sequist & Joel Neal 28: Anti-her 2 Therapies Eric Winer 29: Intracellular Signal Inhibitors (bcr-abl) Bruce Chabner & Jeffrey Barnes 30: Signal Transduction Inhibitors in Development Jeff Clark 31: Inhibitors of the PI3k Pathway & Mitotic Kinase Percy Ivy Section 4: IMMUNOLOGIC AGENTS 32: Interferon and Cytokines David McDermott 33: Vaccines Robert G. Fenton 34: Adoptive Cellular Therapies Cassian Yee 35: Immuno-modulatory Drugs (IMIDS, Anti-CTLA4) Paul Richardson et al. Section 5: HORMONAL THERAPY 36: Hormonal Therapy of Breast Cancer Beverly Moy & Paul Goss 37: GNRH Agonists and Anti-Androgens Richard Lee Section 6: SUPPORTIVE CARE 38: Pain Management in Cancer Patients Paul Glare 39: Colony Stimulating Factors Gary Lyman 40: Anti-nausea Medications Ian Olver 41: Bone Loss Modulators Matthew Smith 42: Intravenous Access and Catheter Management Rachel Rosovsky Section 7: SURVIVORSHIP 43: Monitoring for Late Side Effects of Chemotherapy Richard Schilsky, Charles Erlichman & Brian Costello